A003220 logo

Daewon Pharmaceutical Co., Ltd. Stock Price

KOSE:A003220 Community·₩260.8b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A003220 Share Price Performance

₩12,170.00
-2020.00 (-14.24%)
₩12,170.00
-2020.00 (-14.24%)
Price ₩12,170.00

A003220 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Very undervalued with moderate growth potential.

2 Risks
4 Rewards

Daewon Pharmaceutical Co., Ltd. Key Details

₩590.7b

Revenue

₩325.0b

Cost of Revenue

₩265.7b

Gross Profit

₩280.5b

Other Expenses

-₩14.8b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-690.75
44.98%
-2.51%
79.2%
View Full Analysis

About A003220

Founded
1958
Employees
1283
CEO
Seung-Ryel Baek
WebsiteView website
www.daewonpharm.com

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Recent A003220 News & Updates

Recent updates

No updates